Unrelated DonorsTissue DonorsHistocompatibility TestingBone Marrow TransplantationGraft vs Host DiseaseHistocompatibilityTransplantation, HomologousTransplantation ConditioningHematopoietic Stem Cell TransplantationBone MarrowHematologic NeoplasmsLiving DonorsBlood DonorsCord Blood Stem Cell TransplantationBone Marrow CellsHLA AntigensLeukemiaGraft SurvivalAnemia, AplasticRecurrenceTreatment OutcomeWhole-Body IrradiationAntilymphocyte SerumPeripheral Blood Stem Cell TransplantationDonor SelectionSurvival AnalysisVidarabineMyeloablative AgonistsDisease-Free SurvivalPrecursor Cell Lymphoblastic Leukemia-LymphomaSiblingsTransplantation ChimeraHLA-DP beta-ChainsBusulfanImmunosuppressive AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHematologic DiseasesRetrospective StudiesMyelodysplastic SyndromesSurvival RateLymphocyte DepletionFetal BloodAcute DiseaseLeukemia, Myeloid, AcuteGraft RejectionHLA-DP AntigensTransplantation ImmunologyHemibody IrradiationTissue and Organ ProcurementRemission InductionAllograftsHLA-A AntigensLife TablesDirected Tissue DonationStem Cell TransplantationCyclosporineActuarial AnalysisTransplantation, AutologousHistiocytosis, Non-Langerhans-CellTime FactorsMethotrexateHematopoietic Stem CellsInfectionHLA-B AntigensHLA-C AntigensTacrolimusT-LymphocytesFollow-Up StudiesSevere Combined ImmunodeficiencyTransplantsCyclophosphamideRegistriesBone Marrow DiseasesKidney TransplantationWiskott-Aldrich SyndromeCause of DeathFanconi AnemiaCytomegalovirus InfectionsBone Marrow ExaminationMelphalanGraft vs Leukemia EffectHematopoiesisImmunosuppressionGraft vs Tumor EffectLymphocyte TransfusionMetabolism, Inborn ErrorsHLA-DRB1 ChainsAllelesRisk FactorsAnemia, Refractory, with Excess of BlastsLeukemia, Myelomonocytic, AcuteLeukemia, MyeloidTransplantation, IsogeneicHLA-DR AntigensBlood Cell CountBone Marrow NeoplasmsIncidenceMycophenolic AcidAntibodies, NeoplasmChronic Disease